As a specific result of WP2, it was identified that the stimulation of sex hormone production, reduction of insulin resistance—frequently present in cases of depression and anxiety (34, 35), whether systemic or central (36, 37), as well as associated with leptin resistance (38)—enhancement of hypothalamic activity, increased availability of IGF-1, and potential reduction of mitochondrial dysfunction each lead to various systemic biological benefits. This evidence concerns the gene PLXNA3 and depressive symptom measurement.